Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?

Table 4

Clinical trials combining HDI and HT in advanced/metastatic ER-positive breast carcinoma.

HDI	HT	Phase	Patients	Preliminary results	Reference
Vorinostat (SAHA) 200 mg twice daily 14 d/21	Tam	II	AI resistant HR+	34 patients evaluated; 21% OR; 12% SD	Munster et al. Poster # 6100 SABCS 2009
Entinostat (SNDX275); 5 mg weekly	AI; (Exemestane)	II	AI resistant HR+	10 patients with >2 cycles; CB > 6 months (1 case); CB > 5 months (2 cases)	NCI clinical trial NCT00676663 Yardley et al.; Poster # 6111 SABCS 2009
Vorinostat (SAHA) 200 mg twice daily 14 d/21	AI; (anastrozole letrozole, OR exemestane)	II	AI resistant	Ongoing	NCI clinical trial NCT01153672 Linden et al.
Panobinostat (LBH589) once daily on days 1, 3, 5 during 28 d	AI; (Letrozole)	I/II	HR−/+ (phase I) triple-negative disease (phase II)	Ongoing	NCI clinical trial NCT01105312 Tan et al.
Vorinostat (SAHA)	Tam	II	Stage I–III (treatment for 2 weeks before surgery)	Ongoing	NCI clinical trial NCT01194427 Stearns et al.

AI: aromatase inhibitor. OR: objective response. SD: stable disease. CB: clinical benefice. HR: hormone receptor. SABCS: San Antonio Breast Cancer Symposium 2009.